Novel pyrrolyl-thiazole derivatives

BACKGROUND OF THE INVENTION

[0001] The present invention is concerned with novel pyrrolyl-thiazole derivatives, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention may be useful in treating obesity and other disorders.

[0002] Two different subtypes of cannabinoid receptors (CB1 amd CB2) have been isolated and both belong to G protein coupled receptor superfamily. An alternative spliced form of CB1, CB1A, has also been described, but it did not exhibit different properties in terms of ligand binding and receptor activation than CB1 (D. Shire, C. Carrillon, M. Kaghad, B. Calandra, M. Rinaldi-Carmona, G. Le Fur, D. Caput, P. Ferrara, J. Biol. Chem. 270 (8) (1995) 3726-31). The CB1, receptor is mainly located in the brain, whereas the CB2 receptor is predominately distributed in the periphery and primarily localized in spleen and cells of the immune system (S. Munro, K. L. Thomas, M. Abu-Shaar, Nature 365 (1993) 61-61). Therefore in order to avoid side effects a CB1-selective compound is desirable.

[0003] Δ9-tetrahydrocannabinol (Δ9-THC) is the principal psychoactive compound in the Indian hemp (Y. Gaoni, R. Mechoulam, J. Am. Chem. Soc., 86 (1964) 1646), canabis savita (marijuanan), which is used in medicine since ages (R. Mechoulam (Ed.) in “Cannabinoids as therapeutic Agents”, 1986, pp. 1-20, CRC Press). Δ9-THC is a non-selective CB1/2 receptor agonist and is available in the USA as dronabinol (marinol®) for the alleviation of cancer chemotherapy-induced emesis (CIE) and the reversal of body weight loss experienced by AIDS patients through appetite stimulation. In the UK Nabolinone (LY-109514, Cesamet®), a synthetic analogue of Δ9-THC, is used for CIE (R. G. Pertwee, Pharmaceut. Sci. 3 (11) (1997) 539-545, E. M. Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314).

[0004] Anandamide (arachidonylethanolamide) was identified as the endogenous ligand (agonist) for the CB1 receptor (R. G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664; W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam, Science 258 (1992) 1946-9). Anandamide and 2-arachidonoylglycerol (2-AG) modulate at the presynaptic nerve teminal negatively adenylate cyclase and voltage-sensitive Ca2+ channels and activates the inwardly rectifying K+ channel (V. Di Marzo, D. Melck, T. Bisogno, L. De Petrocellis, Trends in Neuroscience 21 (12) (1998) 521-8), thereby affecting neurotransmitter release and/or action, which decreases the release of neurotransmitter (A. C. Porter, C. C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60).

[0005] Anandamide as Δ9-THC also increases feeding through CB1 receptor-mediated mechanism. CB1 receptor selective antagonists block the increase in feeding associated with administration of anandamide (C. M. Williams, T. C. Kirkham, Psychopharmacology 143 (3) (1999) 315-317; C. C. Felder, E. M. Briley, J. Axelrod, J. T. Simpson, K. Mackie, W. A. Devane, Proc. Natl. Acad. Sci. U.S. A. 90 (16) (1993) 7656-60) and caused appetite suppression and weight loss (G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, G. L. Gessa, Life Sci. 63 (8) (1998) L113-PL117).

[0006] Leptin is the primary signal through which the hypothalamus senses nutritional state and modulates food intake and energy balance. Following temporary food restriction, CB1 receptor knockout mice eat less than their wild-type littermates, and the CB1 antagonist SR141716A reduces food intake in wild-type but not knockout mice. Furthermore, defective leptin signaling is associated with elevated hypothalamic, but not cerebellar, levels of endocannabinoids in obese db/db and ob/ob mice and Zucker rats. Acute leptin treatment of normal rats and ob/ob mice reduces anandamide and 2-arachidonoyl glycerol in the hypothalamus. These findings indicate that endocannabinoids in the hypothalamus may tonically activate CB1 receptors to maintain food intake and form part of the neural circuitry regulated by leptin (V. Di Marzo, S. K. Goparaju, L. Wang, J. Liu, S. Bitkai, Z. Jarai, F. Fezza, G. I. Miura, R. D. Palmiter, T. Sugiura, G. Kunos, Nature 410 (6830) 822-825).

[0007] SR-141716A, a CB1 selective antagonist/inverse agonist is undergoing currently phase III clinical trials for the treatment of obesity. In a double blind placebo-controlled study, at the doses of 5, 10 and 20 mg daily, SR 141716 significantly reduced body weight when compared to placebo (F. Barth, M. Rinaldi-Carmona, M. Arnone, H. Heshmati, G. Le Fur, “Cannabinoid antagonists: From research tools to potential new drugs.” Abstracts of Papers, 222nd ACS National Meeting, Chicago, Ill., United States, Aug. 26-30, 2001).

[0008] Other compounds which have been proposed as CB1 receptor antagonists respectively inverse agonists are aminoalkylindols (AAI; M. Pacheco, S. R. Childers, R. Arnold, F. Casiano, S. J. Ward, J. Pharmacol. Exp. Ther. 257 (1) (1991) 170-183), like 6-bromo-(WIN54661; F. M. Casiano, R. Arnold, D. Haycock, J. Kuster, S. J. Ward, NIDA Res. Monogr. 105 (1991) 295-6) or 6-iodopravadoline (AM630, K. Hosohata, R. M. Quock, R. M; Hosohata, T. H. Burkey, A. Makriyannis, P. Consroe, W. R. Roeske, H. I. Yamamura, Life Sci. 61 (1997) 115-118; R. Pertwee, G. Griffin, S. Fernando, X. Li, A. Hill, A. Makriyannis, Life Sci. 56 (23-24) (1995) 1949-55). Arylbenzo[b]thiophene and benzo[b]furan (LY320135, C. C. Felder, K. E. Joyce, E. M. Briley, M. Glass, K. P. Mackie, K. J. Fahey, G. J. Cullinan, D. C. Hunden, D. W. Johnson, M. O. Chaney, G. A. Koppel, M. Brownstein, J. Pharmacol. Exp. Ther. 284 (1) (1998) 291-7) disclosed in WO9602248, U.S. Pat. No. 5,596,106, 3-alkyl-(5,5-diphenyl)imidazolidinediones (M. Kanyonyo, S. J. Govaerts, E. Hermans, J. H. Poupaert, D. M. Lambert, Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236.) as well as 3-alkyl-5-arylimidazolidinediones (F. Ooms, J. Wouters, O. Oscaro. T. Happaerts, G. Bouchard, P.-A. Carrupt, B. Testa, D. M. Lambert, J. Med. Chem. 45 (9) (2002) 1748-1756) are known to antagonize the CB1 receptor respectively act as an inverse agonist on the hCB1 receptor. WO0015609 (FR2783246-A1), WO0164634 (FR2805817-A1), WO0228346, WO0164632 (FR2805818-A1), WO0164633 (FR2805810-A1) disclosed substituted 1-bis(aryl)methyl-azetidines derivatives as antagonists of CB1. In WO0170700 4,5-dihydro-1H-pyrazole derivatives are described as CB, antagonists. In several patents bridged and non-bridged 1,5-diphenyl-3-pyrazolecarboxamide derivatives are disclosed as CB, antagonists/inverse agonists (WO0132663, WO0046209, WO9719063, EP658546, EP656354, U.S. Pat. No. 5,624,941, EP576357, U.S. Pat. No. 3,940,418).

SUMMARY OF THE INVENTION

[0009] The present invention relates to compounds of formula (I):

[0010] wherein

[0011] R1, R2, R3, R4, R5, R6 and R7 are as herein defined, or a pharmaceutically acceptable salt thereof.

[0012] According to one aspect of the present invention, compounds of formula (I) may be selective, directly acting CB1 receptor antagonists respectively inverse agonists. Such antagonists/inverse antagonists are useful in medical therapy, particularly in the treatment and/or prevention of diseases which are associated with the modulation of CB1 receptors.

[0013] Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

[0014] In this specification the term “lower” is used to mean a group consisting of one to eight, preferably of one to four carbon atom(s).

[0015] The term “halogen” refers to fluorine, chlorine, bromine and iodine, preferably to chlorine and fluorine.

[0016] The term “alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms.

[0017] The term “lower alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to eight carbon atoms, preferably one to four carbon atoms. This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-pentyl, 3-methylbutyl, n-hexyl, 2-ethylbutyl and the like.

[0018] The term “alkoxy” refers to the group R′—O—, wherein R′ is alkyl. The term “lower alkoxy” refers to the group R′—O—, wherein R′ is lower alkyl. Examples of lower alkoxy groups are e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy, with methoxy being especially preferred.

[0019] The term “lower alkenyl” refers to a lower alkyl group containing one or more double bond(s) in the alkylene chain. This term is further exemplified by radicals such as vinyl, 1-propenyl, allyl, 1-butenyl, 2-butenyl and 3-butenyl, with allyl being preferred.

[0020] The term “lower alkylamino” refers to the group R′—NH—, wherein R′ is lower alkyl.

[0021] The term “lower alkoxycarbonyl” refers to the group R′-O—C(O)—, wherein R′ is lower alkyl.

[0022] The term “lower alkoxycarbonylamino” refers to the group R′—O—C(O)NH—, wherein R′ is lower alkyl.

[0023] The term “halogenated lower alkyl” refers to a lower alkyl group wherein at least one of the hydrogens of the lower alkyl group is replaced by a halogen atom, preferably fluoro or chloro. Among the preferred halogenated lower alkyl groups are trifluoromethyl, difluoromethyl, fluoromethyl and chloromethyl, with trifluoromethyl being especially preferred. The term “fluorinated lower alkyl” refers to a lower alkyl group wherein at least one of the hydrogens of the lower alkyl group is replaced by fluoro. Among the preferred fluorinated lower alkyl groups are trifluoromethyl, difluoromethyl and fluoromethyl, with trifluoromethyl being especially preferred.

[0024] The term “halogenated lower alkoxy” refers to a lower alkoxy group wherein at least one of the hydrogens of the lower alkoxy group is replaced by halogen, preferably by fluorine or chlorine. Among the preferred halogenated lower alkoxy groups are fluorinated lower alkoxy groups such as trifluoromethoxy, difluoromethoxy and fluoromethoxy, with trifluoromethoxy being especially preferred. The term “fluorinated lower alkoxy” refers to a lower alkoxy group wherein at least one of the hydrogens of the lower alkoxy group is replaced by fluoro. Among the preferred fluorinated lower alkoxy groups are trifluoromethoxy, difluoromethoxy and fluoromethoxy, with trifluoromethoxy being especially preferred.

[0025] The term “di-phenyl-lower alkyl” refers to a lower alkyl group wherein two of the hydrogens of the lower alkyl group is replaced by phenyl. The phenyl moiety may optionally be mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy or halogen.

[0026] The term “phenoxy-lower alkyl” refers to a lower alkyl group wherein one of the hydrogens of the lower alkyl group is replaced by phenoxy. The phenyl moiety of the phenoxy-lower alkyl residues may optionally be mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy or halogen.

[0027] The term “cycloalkyl” refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0028] The term “cycloalkenyl” refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms, which carbocyclic ring contains at least on double bond. This term is further exemplified by radicals such as cyclobutenyl, cyclopentenyl and cyclohexenyl, with cyclohexenyl being preferred.

[0029] The term “pharmaceutically acceptable salts” embraces salts of the compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, salicylic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms. Preferred salts with acids are formates, maleates, citrates, hydrochlorides, hydrobromides and methanesulfonic acid salts, with hydrochlorides being especially preferred.

DETAILED DESCRIPTION OF THE INVENTION

[0030] In particular, the present invention relates to compounds of formula (I):

[0031] wherein

[0032] R1 is hydrogen, or lower alkyl;

[0033] R2 is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH2)m—R2a or —NHC(O)—R2a;

[0034] or R1 and R2 together with the nitrogen atom to which they are attached form a 5-or 6-membered, saturated heterocyclic ring optionally containing one or two further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy;

[0035] R2a is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

[0036] R3 is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH2)n—R3a;

[0037] R3a is cycloalkyl fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

[0038] R4 is lower alkyl, lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH2)p—O— or —(CH2)2—O—;

[0039] R5 and R6 are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl;

[0040] R7 is hydrogen, lower alkyl or halogen;

[0041] m is 0, 1, 2 or 3;

[0042] n is 0, 1, 2, 3 or 4;

[0043] p is 1, 2 or 3;

[0044] or a pharmaceutically acceptable salts thereof.

[0045] In one embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R1 is hydrogen or lower alkyl.

[0046] Preferable lower alkyl residues R1 are methyl and ethyl, with methyl being especially preferred. Most preferably, R1 is hydrogen.

[0047] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R2 is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH2)m—R2a or —NHC(O)—R2a.

[0048] Preferable lower alkyl residues R2 are branched or straight chain alkyl residues with one to eight, preferably three to five carbon atoms, such as n-propyl, n-butyl, s-butyl, isobutyl, n-pentyl and 2-ethylhexyl. Most preferred lower alkyl residues R2 are n-propyl, n-butyl, s-butyl, isobutyl and n-pentyl. Preferable lower alkenyl residues R2 are 1-butenyl and allyl, with allyl being especially preferred. Preferable lower alkoxy-lower alkyl residues R2 are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl and ethoxypropyl, with methoxyethyl and methoxypropyl being especially preferred. Preferable lower alkoxycarbonylamino groups R2 are methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino and butoxycarbonylamino, with ethoxycarbonylamino being especially preferred. Preferable residues R2 are lower alkyl as defined above, —(CH2)m—R2a or —NHC(O)—R2a, wherein R2a is as defined below and m is 0 or 1, preferably 0. Most preferable residues R2 are lower alkyl as defined above or —(CH2)m—R2a, wherein R2a is as defined below and m is 0 or 1, preferably 0.

[0049] In one embodiment, R2a is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro.

[0050] Preferable cycloalkyl residues R2a are cycloalkyl residues with three to six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, which may optionally be mono-, di-, tri-or tetra-substituted, preferably mono-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy, preferably by lower alkyl, such as methyl, and/or hydroxy. Most preferable cycloalkyl residues R2a are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 2-hydroxycyclopentyl.

[0051] Preferable cycloalkenyl residues R2a are cyclobutenyl, cyclopentenyl and cyclohexenyl, with cyclohexenyl, preferably cyclohex-1-enyl, being especially preferred. Preferable heterocyclic rings R2a are 5-or 6-memberd, with 5-membered being especially preferred, and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy. Preferably, heterocyclic rings R2a are unsubstituted. Most preferred heterocyclic rings R2a are piperidinyl, morpholino and tetrahydrofuranyl, with piperidinyl and morpholino being especially preferred. Preferable heteroaromatic rings R2a are 5-or 6-membered and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino. Examples of heteroaromatic rings R2a are pyridinyl, pyrimidinyl, thiazolyl and isoxazolyl, optionally substituted as defined above. Preferably, heteroaromatic rings R2a are unsubstituted or mono-substituted by lower alkyl, preferably methyl. Most preferable heteroaromatic rings R2a are pyridinyl, pyrimidinyl, 4-methylthiazolyl or 5-methylisoxazolyl. Preferable phenyl residues R2a are optionally mono-, di- or tri-substituted, preferably mono-or di-substituted, independently, by lower alkoxy, such as methoxy, halogen, such as chloro, halogenated lower alkyl, such as trifluoromethyl, halogenated lower alkoxy, such as trifluoromethoxy, or nitro. Most preferable phenyl residues R2a are unsubstituted phenyl, 4-trifluoromethyl-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3,4-dimethoxy-phenyl, 2-nitro-phenyl and 4-trifluoromethoxy-phenyl. Preferably, m is 0, 1 or 2, more preferably m is 0 or 1, most preferably m is 0.

[0052] In another embodiment, R1 and R2 together with the nitrogen atom to which they are attached form a 5- or 6-membered, saturated heterocyclic ring optionally containing one or two, preferably one, further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, preferably oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy. Preferably, heterocyclic rings formed by R1 and R2 together with the nitrogen atom to which they are attached are unsubstituted, with unsubstituted pyrrolidinyl, piperidinyl and morpholino being especially preferred.

[0053] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R3 is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH2)n—R3a.

[0054] Preferable lower alkyl residues R3 are branched or straight chain alkyl residues with one to six, preferably four carbon atoms, such as ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, n-pentyl and n-hexyl. Most preferred lower alkyl residues R3 are n-butyl and s-butyl. Preferable lower alkenyl residues R3 are 1-butenyl and allyl, with allyl being especially preferred. Preferable lower alkoxy-lower alkyl residues R3 are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl and ethoxypropyl, with methoxyethyl and methoxypropyl being especially preferred. Preferable di-phenyl-lower alkyl is di-phenyl-methyl. Most preferably, R3 is a residue —(CH2)n—R3a, wherein R is as defined below and n is 1 or 2, preferably 1.

[0055] In one embodiment, R3a is cycloalkyl fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro.

[0056] Preferable cycloalkyl residues R3a are cycloalkyl residues with five or six carbon atoms, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy, or which may optionally be fused to a phenyl ring. Preferably, cycloalkyl residues R3a are unsubstituted, such as unsubstituted cyclopentyl or unsubstituted cyclohexyl, with unsubstituted cyclohexyl being preferred, or fused to a phenyl residue, such as indanyl. Preferable cycloalkenyl residues R2a are cyclobutenyl, cyclopentenyl and cyclohexenyl, with cyclohexenyl, preferably cyclohex-1-enyl, being especially preferred. Preferable heterocyclic rings R3a are 5-or 6-memberd and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy. Examples of heterocyclic rings R3a are piperidinyl, morpholino and pyrrolidinyl, optionally substituted as defined above. Preferably, heterocyclic rings R3a are unsubstituted or substituted by lower alkyl, such as methyl or ethyl, with ethyl being especially preferred. Most preferred heterocyclic rings R3a are piperidinyl, morpholino and 1-ethyl-pyrrolidinyl. Preferable heteroaromatic rings R3a are 5-or 6-membered and contain one to three, preferably one, heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino. Examples of heteroaromatic rings R3a are furyl, thienyl and pyridinyl, optionally substituted as defined above. Preferably, heteroaromatic rings R3a are unsubstituted or mono-substituted by lower alkyl, preferably methyl. Most preferable heteroaromatic rings R3a are furyl, thienyl, 3-methylthienyl and pyridinyl. Preferable phenyl residues R3a are optionally mono-, di- or tri-substituted, preferably mono-or di-substituted, most preferably mono-substituted, independently, by hydroxy, lower alkyl, such as methyl or isopropyl, lower alkoxy, such as methoxy, halogen, such as chloro, halogenated lower alkyl, such as trifluoromethyl, halogenated lower alkoxy, such as trifluoromethoxy, or nitro. Most preferable phenyl residues R3a are unsubstituted phenyl, 2-methyl-phenyl, 4-methyl-phenyl, 3,4-dimethyl-phenyl, 3,5-dimethyl-phenyl, 4-isopropyl-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3,5-dichloro-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 3,4,5-trimethoxy-phenyl, 3-trifluoromethoxy-phenyl, 4-trifluoromethoxy-phenyl, 3-trifluormethyl-4-chlorophenyl and 4-nitro-phenyl, with 4-methoxy-phenyl being especially preferred. Most preferable residue R3a is a phenyl residue as defined above.

[0057] Preferably, n is 0, 1, 2 or 3, more preferably n is 1 or 2, most preferably n is 1.

[0058] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R4 is lower alkyl; lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH2)p—O— or —(CH2)2—O—.

[0059] Preferable lower alkyl residues R4 are branched or straight chain alkyl residues with one to six, preferably one to three carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, isobutyl and n-pentyl. Most preferred lower alkyl residue R4 is methyl. Preferable lower alkoxycarbonylamino groups R4 are methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino and butoxycarbonylamino, with ethoxycarbonylamino being especially preferred. Preferable cycloalkyl residues R4 are cycloalkyl residues with three to six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, which may optionally be mono-, di-, tri-or tetra-substituted, preferably mono-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy, preferably by lower alkyl, such as methyl, and/or hydroxy. Most preferable cycloalkyl residue R4 is unsubstituted cyclohexyl. Preferable heteroaromatic rings R4 are 5-or 6-membered and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino. Examples of heteroaromatic rings R4 are pyridinyl, pyrazinyl and thiazolyl, optionally substituted as defined above. Preferably, heteroaromatic rings R4 are unsubstituted or mono-substituted by lower alkyl, such as methyl and ethyl, or by lower alkoxy, such as methoxy. Most preferable heteroaromatic rings R4 are 2-methoxy-pyridinyl, 2-methyl-pyridinyl, pyrazinyl and 2-methyl-thiazolyl.

[0060] Preferable phenoxy-lower alkyl residues R4 are phenoxy-methyl and phenoxy ethyl, wherein the phenyl moiety may optionally be mono-substituted by lower alkoxy, such as methoxy. Most preferable phenoxy-lower alkyl residue R4 is 3-methoxy-phenoxy-methyl.

[0061] Preferable phenyl residues R4 are mono-, di- or tri-substituted, preferably mono-or di-substituted, most preferably mono-substituted, independently, by hydroxy, lower alkyl, such as methyl, ethyl or t-butyl, lower alkoxy, such as methoxy, halogen, such as chloro or fluoro, halogenated lower alkyl, such as trifluoromethyl, halogenated lower alkoxy, such as trifluoromethoxy or nitro. Alternatively, two adjacent substituents of the said phenyl residue together may be —O—(CH2)p—O— or —(CH2)2—O—, wherein p is 1, 2 or 3, preferably 1 or 2, most preferably 1. Preferable substituents of phenyl residues R4 are nitro and lower alkoxy, or two adjacent substituents being —O—CH2—O—. Most preferable substituted phenyl residues R4 are 2-methyl-phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-t-butyl-phenyl, 2-chloro-phenyl, 4-chloro-phenyl, 2,4-dichloro-phenyl, 2-fluoro-phenyl, 4-fluoro-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 4-hydroxy-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-nitro-phenyl, benzo[1,3]dioxolyl and 2,3-dihydro-benzofuranyl, with 4-methoxyphenyl, 4-nitro-phenyl and benzo[1,3]dioxolyl being especially preferred.

[0062] Preferable residues R4 are cycloalkyl residues and substituted phenyl residues as defined above.

[0063] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R5 and R6 are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl.

[0064] Preferable lower alkyl residues R5 and R6 are methyl and ethyl, with methyl being especially preferred. Preferable halogen residues R5 and R6 are fluoro and chloro, with chloro being especially preferred. Preferable residue R5 is lower alkyl, such as methyl. Preferable residues R6 are hydrogen and lower alkyl, such as methyl.

[0065] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R7 is hydrogen, lower alkyl or halogen.

[0066] Preferable lower alkyl residues R7 are methyl and ethyl, with methyl being especially preferred. Preferable halogen residues R7 are fluoro and chloro, with chloro being especially preferred. Preferable residue R7 are hydrogen and lower alkyl, such as methyl.

[0067] Preferred compounds of general formula (I) are the compounds of Examples 1 to 377, preferably 1 to 375 (see section Examples below) and pharmaceutically acceptable salts thereof.

[0068] Especially preferred are the compounds selected from the group consisting of:

[0069] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid butylamide,

[0070] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid butylamide,

[0071] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid sec-butylamide,

[0072] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrr ole-3-carboxylic acid sec-butylamide,

[0073] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid isobutyl-amide,

[0074] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid isobutyl-amide,

[0075] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid isobutyl-amide,

[0076] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid allylamide,

[0077] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid cyclohexylmethyl-amide,

[0078] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxy lic acid cyclohexylmethyl-amide,

[0079] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid cyclohexylmethyl-amide,

[0080] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-py rrole-3-carboxylic acid cyclohexylmethyl-amide,

[0081] 4-[1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic acid ethyl ester,

[0082] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,

[0083] N′-{1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carbonyl}-hydrazinecarboxylic acid ethyl ester,

[0084] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide,

[0085] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone,

[0086] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid phenylamide,

[0087] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pyrimidin-2-ylamide,

[0088] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (5-hydroxy-2,2,6-trimethyl-cyclohexylmethyl)-amide,

[0089] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic acid butylamide,

[0090] Benzyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0091] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-pyrrolidin-1-yl-methanone,

[0092] Cyclohexylmethyl-5-[2-(3,4-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0093] Cyclohexylmethyl-5-[2-(3-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0094] 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0095] Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0096] Cyclohexylmethyl-5-[2-(2-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0097] Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide,

[0098] Cyclohexylmethyl-5-[2-(3,5-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0099] Cyclohexylmethyl-2-methyl-5-(2-m-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0100] Cyclohexylmethyl-2-methyl-5-(2′-methyl-[2,4′]bithiazolyl-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0101] Cyclohexylmethyl-5-[2-(4-ethyl-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0102] 5-[2-(4-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0103] 5-[2-(4-tert-Butyl-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0104] Cyclohexylmethyl-5-[2-(2,3-dihydro-benzofuran-5-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0105] Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0106] Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0107] Cyclohexylmethyl-5-[2-(2,4-dichloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0108] Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide,

[0109] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pentylamide,

[0110] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid propylamide,

[0111] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,

[0112] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopentylamide,

[0113] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylamide,

[0114] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclobutylamide,

[0115] (trans) rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-cyclopentyl)-amide,

[0116] 1-(4-Chloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0117] 1-(3,4-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0118] 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0119] 1-(3,4-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0120] Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0121] 1-(4-Isopropyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0122] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid butylamide,

[0123] Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0124] and pharmaceutically acceptable salts thereof.

[0125] Most preferred compounds of general formula (I) are those selected from the group consisting of:

[0126] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid butylamide,

[0127] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide,

[0128] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone,

[0129] 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0130] Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0131] Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0132] Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0133] Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide,

[0134] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pentylamide,

[0135] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,

[0136] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopentylamide,

[0137] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylamide,

[0138] Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0139] Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0140] or a pharmaceutically acceptable salt thereof.

[0141] The present invention also relates to a process for the manufacture of compounds of formula (I) as defined above. The compounds of formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to the person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below or in the Examples or by methods known in the art.

[0142] The compounds of formula (I) may be prepared using the general methods described below:

[0143] Compounds of formula (I), wherein R1 to R7 and m are as previously defined, can be prepared by reaction of enamines of formula A with alfa-bromoketones of formula B according to methods known in the art (Scheme 1). For example, the reaction can be performed in an inert solvent such as DMF in the presence of a hindered base such as 2,6-di-tert-butylpyridine or 2,6-lutidine.

[0144] Compounds of formula I can be purified by methods known in the art such as precipitation from mixtures of solvents (e.g. acetonitrile and water) or by column chromatography using SiO2 with eluents know in the art (e.g. n-heptane/Ethyl acetate, dichloromethane/methanol and dichloromethane/(1% NH3 in MeOH)).

[0145] Thiazole derivatives of formula B can be prepared from dibromodiketones of formula C and thioamides of formula C by methods known in the art (Scheme 2). For example, the reaction can be performed by addition of thioamides of formula C to dibromo-diketones of formula D in an inert solvent such as DMF.

[0146] Enamines of formula A can be prepared from beta-ketoamides of formula E and amines of formula F by methods known in the art (Scheme 3). For example a beta-keto amide of formula E can be reacted with an amine of formula B in a suitable inert solvent (e.g. DMF) in the presence of a hindered base (e.g. 2,6-di-tert-butylpyridine) to yield enamine of formula A.

[0147] Beta-ketoamides of formula E are either known form the literature or can be purchased from commercial sources or else can be prepared by methods known in the art. For example, beta-ketoamides of formula E wherein R5═methyl can be prepared by reaction of amines of formula G with diketene in an inert solvent such as dichloromethane (Scheme 4).

[0148] Compounds of formula D, F and G are either known from the literature or can be purchased from commercial sources or else can be synthesized by methods known in the art.

[0149] The invention further relates to compounds of formula (I) as defined above, when manufactured according to a process as defined above.

[0150] Some compounds of formula (I) may possess asymmetric centres and are therefore capable of existing in more than one stereoisomeric form. The invention thus also relates to compounds in substantially pure isomeric form at one or more asymmetric centres as well as mixtures, including racemic mixtures, thereof. Such isomers may be prepared by asymmetric synthesis, for example using chiral intermediate, or mixtures may be resolved by conventional mehtods, eg., chromatography (chromatography with a chiral adsorbens or eluent), or use of a solving agent.

[0151] It will be appreciated, that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.

[0152] As described above, the compounds of formula (I) or pharmaceutically acceptable salts thereof can be used as medicaments for the treatment and/or prophylaxis of diseases which are associated with the modulation of the CB1 receptors.

[0153] The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.

[0154] Further, the invention relates to compounds as defined above for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

[0155] In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, which method comprises administering a compound as defined above to a human being or animal.

[0156] The invention further relates to the use of compounds as defined above for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

[0157] In addition, the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors. Such medicaments comprise a compound as defined above.

[0158] In this context, the expression ‘diseases associated with modulation of CB1 receptors’ means diseases which can be treated and/or prevented by modulation of CB1 receptors. Such diseases encompass, but are not limited to, psychic disorders, especially anxiety, psychosis, schizophrenia, depression, abuse of psychotropes, for example for the abuse and/or dependence of a substances, including alcohole dependency and nicotine dependency, neuropathies, migraine, stress, epilepsy, dyskinesias, Parkinson's disease, amnesia, cognitive disorders, senile dementia, Alzheimer's disease, eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), gastrointestinal diseases, vomiting, diarrhea, urinary disorders, cardiovascular disorders, infertility disorders, inflammations, infections, cancer, neuroinflammation, in particular in atherosclerosis, or the Guillain-Barré syndrome, viral encephalitis, cerebral vascular incidents and cranial trauma.

[0159] In a preferable aspect, the expression ‘diseases associated with modulation of CB1 receptors’ relates to eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, abuse and/or dependence of a substances, including alcohole dependency and nicotine dependency. In a more preferable aspect, the said term related to eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), abuse and/or dependence of a substances, including alcohole dependency and nicotine dependency, with obesity being especially preferred.

[0160] It is a further preferred object to provide a method of treatment or prevention of Type II diabetes (non-insulin dependent diabetes mellitus (NIDDM) in a human which comprises administration of a therapeutically effective amount of a compound according to formula (I) in combination or association with a therapeutically effective amount of a lipase inhibitor, particularly, wherein the lipase inhibitor is orlistat. Also an object of the invention is the method as described above for the simultaneous, separate or sequential administration of a compound according to formula (I) and a lipase inhibitor, particularly tetrahydrolipstatin.

[0161] It is a further preferred object to provide a method for the treatment or prevention of obesity and obesity related disorders which comprises administration of a therapeutically effective amount of a compound according to formula (I) in combination or association with a therapeutically effective amount of other drugs for the treatment of obesity or eating disorders so that together they give effective relief. Suitable other drugs include but are not limited to anorectic agents, lipase inhibitors and selective serotonin reuptake inhibitors (SSRI). Combinations or associations of the above agents may be encompassing separate, sequential or simultaneous administration.

[0162] Preferable lipase inhibitor is tetrahydrolipstatin.

[0163] Suitable anorectic agents of use in combination with a compound of the present invention include, but are not limited to, aminorex, amphechloral, amphetamine, benzphetamine, chlorphentermine, clobenzorex, cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine, dextroamphetamine, diethylpropion, diphemethoxidine, N-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex, fenproporex, fludorex, fluminorex, furfurylmethylamphetamine, levamfetamine, levophacetoperane, mazindol, mefenorex, metamfepramone, methamphetamine, norpseudoephedrine, pentorex, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picilorex and sibutramine, and pharmaceutically acceptable salts thereof.

[0164] Most preferable anorectic agents are sibutramine and phentermine.

[0165] Suitable selective serotonin reuptake inhibitors of use in combination with a compound of the present invention include: fluoxetine, fluvoxamine, paroxetine and sertraline, and pharmaceutically acceptable salts thereof.

[0166] Demonstration of additional biological activities of the compounds of the present invention may be accomplished through in vitro, ex vivo, and in vivo assays that are well known in the art. For example, to demonstrate the efficacy of a pharmaceutical agent for the treatment of obesity-related disorders such as diabetes, Syndrome X, or atherosclerotic disease and related disorders such as hypertriglyceridemia and hypercholesteremia, the following assays may be used.

[0167] Method for Measuring Blood Glucose Levels

[0168] db/db mice (obtained from Jackson Laboratories, Bar Harbor, Me.) are bled (by either eye or tail vein) and grouped according to equivalent mean blood glucose levels. They are dosed orally (by gavage in a pharmaceutically acceptable vehicle) with the test compound once daily for 7 to 14 days. At this point, the animals are bled again by eye or tail vein and blood glucose levels are determined.

[0169] Method for Measuring Triglyceride Levels

[0170] hApoAl mice (obtained from Jackson Laboratories, Bar Harbor, Me.) are bled (by either eye or tail vein) and grouped according to equivalent mean serum triglyceride levels. They are dosed orally (by gavage in a pharmaceutically acceptable vehicle) with the test compound once daily for 7 to 14 days. The animals are then bled again by eye or tail vein, and serum triglyceride levels are determined. Method for Measuring HDL-Cholesterol Levels

[0171] To determine plasma HDL-cholesterol levels, hApoAl mice are bled and grouped with equivalent mean plasma HDL-cholesterol levels. The mice are orally dosed once daily with vehicle or test compound for 7 to 14 days, and then bled on the following day. Plasma is analyzed for HDL-cholesterol.

[0172] In addition, to demonstrate CNS activities of the compounds of the present invention, the following in vivo assays may be used.

[0173] Method for Testing Task Learning and Spatial Memory

[0174] The Morris Water Maze is routinely used to assess task learning and spatial memory (Jaspers et al., Neurosci. Lett. 117:149-153, 1990; Morris, J. Neurosci. Methods 11:47-60, 1984). In this assay, animals are placed in a water pool which is divided into quadrants. One platform is hidden in one of the quadrants. The animal is placed in the water pool and is expected to locate the hidden platform within a predetermined time. During a number of training trials, the animal learns the location of the platform and escape from the pool. The animal receives multiple trials in this task. Total distance traveled, number of trials to locate platform, latency to find platform, and the swimming path is recorded for each animal. The animal's learning ability is measured by the length of time or number of trials required to find the hidden platform. Memory deficit or improvement is determined by the number of trials or the latency to find the platform at predetermined delay time after acquisition. Leaning and memory may be measured by the number of times that the animal crosses the quadrant where the platform was located during the acquisition phase.

[0175] Method for Testing Drug Dependence

[0176] Self-administration in animals is a predictor of a compound's abuse potential in humans. Modifications to this procedure may also be used to identify compounds that prevent or block the reinforcing properties of drugs that have abuse potential. A compound that extinguishes the self-administration of a drug may prevent that drug's abuse or its dependence. (Ranaldi et al., Psychopharmacol. 161:442-448, 2002; Campbell et al., Exp. Clin. Psychopharmacol. 8:312-25, 2000). In a self-administration test, animals are placed in the operant chambers containing both an active and inactive lever. Each response on the active lever produces an infusion of either the test compound or a drug known to be self-administered. Presses on the inactive lever have no effect, but are also recorded. Animals are then trained to self-administer compound/drug over a set period of time by having drug access during each daily session. Illumination of the chamber house light signals the beginning of the session and the availability of the compound/drug. When the session ends, the house light is turned off. Initially, a drug infusion occurs with every press of the active lever. Once lever-pressing behavior has been established, the number of presses to produce a drug infusion is increased. After stable compound/drug self-administration is obtained, the effect of a second compound on the drug-reinforced behavior may be evaluated. Administration of this second compound prior to the session can either potentiate, extinguish, or produce no change to the self-administrating behavior.

[0177] The following tests were carried out in order to determine the activity of the compounds of formula (I).

[0178] The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using membrane preparations of human embryonic kidney (HEK) cells in which the human cannabis CB1 receptor is transiently transfected using the Semliki Forest Virus system in conjunction with [3H]-CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.

[0179] The affinity of the compounds of the invention for cannabinoid CB2 receptors was determined using membrane preparations of human embryonic kidney (HEK) cells in which the human cannabis CB2 receptor is transiently transfected using the Semliki Forest virus system in conjunction with [3H]-CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.

[0180] The cannabinoid CB1 antagonistic activity of compounds of the invention was determined by functional studies using CHO cells in which human cannabinoid CB1 receptors are stably expressed (see M. Rinaldi-Carmona et. al., J. Pharmacol. Exp. Ther. 278 (1996) 871).

[0181] The stable expression of the human cannabinoid receptor in cell systems was first described in Nature 1990, 346, 561-564 (CB1) and Nature 1993, 365, 61-65 (CB2) respectively. Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CB1 receptors by CB1 receptor agonist (e.g., CP-55,940 or (R)-WIN-55212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration dependent manner. This CB1 receptor mediated response can be antagonised by CB1 receptor antagonists such as the compounds of the invention,

[0182] The compounds of formula (I) show an excellent affinity for the CB1 receptor, determined with the experimental conditions described in Devane et.al. Mol. Pharmacol. 34 (1988) 605-613. The compounds of the present invention or the pharmaceutically acceptable salts or sovants are antagonists and selective for the CB1 receptor with affinites below IC50=2 μM. They exhibit at least a 10 fold selectivity against the CB2 receptor.

1Compound of ExampleIC50 [μM]8<2299<2305<2311<2315<2324<2333<2340<2356<2371<2375<2

[0183] Effect of CB1 Receptor Antagonist/Inverse Agonist on CP 55,940-induced Hypothermia in NMRI Mice

[0184] Animals

[0185] Male NMRI mice were used in this study and were obtained from Research Consulting Company Ltd (RCC) of Fillinsdorf (Switzerland). Mice, weighing 30-31 g were used in this study. Ambient temperature is approximately 20-21° C. and relative humidity 55-65%. A 12 hours light-dark cycle is maintained in the rooms with all tests being performed during the light phase. Access to tap water and food are ad libitum.

[0186] Method

[0187] All measurements were made between 12:00 am and 5:00 pm. Mice were brought in this environment and habituated for at least two hours before the start of the experiment. They had always free access to food and water. For each dose, 8 mice were used. Rectal body temperature measurements were recorded by mean of a rectal probe (RET2 of Physitemp) and digital thermometer (Digi-sense n°8528-20 of Cole Parmer, Chicago USA). The probe was inserted about 3.5 cm in each mouse.

[0188] The body temperature was taken 15 min before administration of either Vehicle or CB1 receptor antagonist/inverse agonist. 30 or 90 min after i.p. or p.o. administration of this compound, respectively, rectal body temperature was recorded in order to evaluate any influence of the compound itself. The CB receptor agonist CP 55,940 (0.3 mg/kg) was immediately administered intravenously, then 20 min after i.v. administration of CP 55940, body temperature was again measured.

[0189] The In Vivo Activity of Compounds of Formula (1) was Assessed for their Ability to Regulate Feeding Behaviour by Recording Food Consumption in Food Deprived Animals.

[0190] Rats were trained to have access to food for 2 h per day and were food deprived for 22 h. When they were trained under this schedule, the amount of food taken every day during these 2 h food intake session was consistent day after day.

[0191] To test the ability of compounds of formula (1) to decrease food intake, 8 animals were used in a cross-over study. Rats were individually housed in Plexiglas boxes with a grid on the floor and a paper was placed below the cage floor to collect any spillage. A food dispenser (becher) filled with a pre-weighed amount of food was presented to them for 2 h. At the end of the food intake session, rats returned to their home cage. Each rat was weighed before the start of the experiment and the amount of food consumed during this 2 h food intake session was recorded. Either various doses of test compound or vehicle was administered orally 60 min before the 2 h food intake session. A positive control Rimonabant (SR141716) was included in the experiment. An Anova analysis with repeated measures was used followed by a posthoc test Student Neumann-Keuls. *P<0.05 compared to Saline-treated rats.

[0192] Furthermore the utility of compounds of formula (1) in diseases or disorders may be demonstrated in animal disease models that have been reported in the literature. The following are examples of such animal disease models: a) reduction of sweet food intake in marmosets (Behavioural Pharm, 1998, 9,179-181); b) reduction of sucrose and ethanol intake in mice (Psychopharm. 1997, 132, 104-106); c) increased motor activity and place conditioning in rats (Psychopharm. 1998, 135, 324-332; Psychopharmacol 2000, 151: 25-30); d) spontaneous locomotor activity in mice (J. Pharm. Exp. Ther. 1996, 277, 586-594); e) reduction in opiate self-administration in mice (Sci. 1999, 283, 401-404);

[0193] The compounds of formula (I) and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.

[0194] The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula (I) and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

[0195] Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).

[0196] Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

[0197] Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

[0198] The dosage of the compounds of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.

[0199] The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula (I).

[0200] The following Examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

EXAMPLES

[0201] MS=mass spectrometry; ISP=ion spray (positive ion), corresponds to ESI and ES+ (electrospray, positive ion); mp=melting point.

Example 1

Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0202]

[0203] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-nitrophenyl thioamide as R4C(S)NH2, as follows:

[0204] Synthesis of 2-bromo-1-[2-(4-nitro-phenyl)-thiazol-4-yl]-ethanone (Compound B)

[0205] To a solution of 1.4 g of 1,4-dibromo-2,3-butanedione in dimethylformamide (110 ml) at room temperature was added 1.4 ml of 2,6-di-tert-butylpyridine. Then a solution of 1.0 g of 4-nitro-phenyl-thiobenzamide in 20 ml of dimethylformamide was slowly added to the reaction mixture over 1 hour. The reaction mixture was then allowed to stir for an additional hour at room temperature before being concentrated in vacuo. The residue was then purified by chromatography over a short column (SiO2, 120 g, CH2Cl2 100%). The isolated compound was triturated with isopropylether to yield 771 mg of the title compound as a yellow solid, mp=186-187° C., MS (EI) 326(M).

[0206] Synthesis of 1-Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0207] To a solution of 4.2 g of diketene in dichloromethane (70 ml) cooled at 0° C. was added over 1 hour a solution of 3.7 g of butylamine in 50 ml of dichloromethane. The reaction mixture was then stirred for one hour at 0° C. and then let to stir at room temperature for another hour. The reaction mixture was then concentrated in vacuo and the crude residue was partitioned in batches which were directly used in the next step.

[0208] To 180 mg of the previous crude material in 5 ml of dimethylformamide was added 0.15 ml of cyclohexylmethylamine together with 0.13 ml of trimethyl orthoformate and the reaction mixture was stirred for 24 hours at room temperature. After such time, 260 mg of 2-bromo-1-[2-(4-nitro-phenyl)-thiazol-4-yl]-ethanone was added together with 0.14 ml of 2,6-lutidine and the reaction mixture was stirred for another 24 hours at room temperature. After such time, 5 ml of a MeCN—H2O (1:1) solution is added to the reaction mixture, the precipitate is filtrated and washed with MeCN—H2O (1:1) and isopropylether to yield 264 mg of the title compound as a yellow solid, mp=184-187° C., MS (ISP) 481.3 (M+H)+.

[0209] Examples 2-375 were synthesized in analogy to Example 1, using the indicated educts.

Example 2

[0210] Butyl-5-[2-(2-chloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0211] The title compound was obtained using butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thiobenzamide as R4C(S)NH2, MS(ES+) 430 (M+H)+.

Example 3

[0212] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0213] The title compound was obtained using butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxy-phenyl thiobenzamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 4

[0214] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0215] The title compound was obtained using butylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thiobenzamide as R4C(S)NH2, MS(ES+) (M+H)+.

Example 5

[0216] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Butylamide

[0217] The title compound was obtained using butylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 4-methoxy-phenyl thiobenzamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 6

[0218] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0219] The title compound was obtained using butylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 398 (M+H)+.

Example 7

[0220] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0221] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thiobenzamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 8

[0222] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0223] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxy-phenyl thiobenzamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 9

[0224] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0225] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 10

[0226] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Butylamide

[0227] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridinecarbothioamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 11

[0228] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0229] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 438 (M+H)+.

Example 12

[0230] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0231] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-chlorophenyl thioamide as R4C(S)NH2, MS(ES+) 458 (M+H)+.

Example 13

[0232] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0233] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxy-phenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 14

[0234] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0235] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 484 (M+H)+.

Example 15

[0236] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0237] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothioamide as R4C(S)NH2, MS(ES+) 453 (M+H)+.

Example 16

[0238] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0239] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothiamide as R4C(S)NH2, MS(ES+) 439 (M+H)+.

Example 17

[0240] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0241] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and pyrazine-2-carbothiamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 18

[0242] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0243] The title compound was obtained using butylamine as R1R2NH, 2-methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxy-phenyl thioamide as R4C(S)NH2, MS(ES+) 428 (M+H)+.

Example 19

[0244] 1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0245] The title compound was obtained using butylamine as R1R2NH, 2-methoxyethylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 400 (M+H)+.

Example 20

[0246] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0247] The title compound was obtained using butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-chlorophenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 21

[0248] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0249] The title compound was obtained using butylamine as R1R2NH, 3-(aminomethyl)-thiophene as R3—(CH2)m—NH2 and 4-methoxy-phenyl thioamide as R4C(S)NH2, MS(ES+) 450 (M+H)+.

Example 22

[0250] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0251] The title compound was obtained using butylamine as R1R2NH, 3-furyl methylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothioamide as R4C(S)NH2, MS(ES+) 449 (M+H)+.

Example 23

[0252] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0253] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-chlorophenyl thioamide as R4C(S)NH2, MS(ES+) 494 (M+H)+.

Example 24

[0254] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0255] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 490 (M+H)+.

Example 25

[0256] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0257] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 520 (M+H)+.

Example 26

[0258] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0259] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 489 (M+H)+.

Example 27

[0260] 4-[4-Butylcarbamoyl-1-(4-methoxy-benzyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0261] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 28

[0262] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0263] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 475 (M+H)+.

Example 29

[0264] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0265] The title compound was obtained using butylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)n—NH2 and pyrazine-2-carbothiamide as R4C(S)NH2, MS(ES+) 462 (M+H)+.

Example 30

[0266] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0267] The title compound was obtained using butylamine as R1R2NH, methoxypropylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 442 (M+H)+.

Example 31

[0268] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0269] The title compound was obtained using butylamine as R1R2NH, methoxypropylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethane thioamide as R4C(S)NH2, MS(ES+) 472 (M+H)+.

Example 32

[0270] 4-[4-Butylcarbamoyl-1-(3-methoxy-propyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0271] The title compound was obtained using butylamine as R1R2NH, methoxypropylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 408 (M+H)+.

Example 33

[0272] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0273] The title compound was obtained using butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 34

[0274] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0275] The title compound was obtained using butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 35

[0276] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0277] The title compound was obtained using butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 36

[0278] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0279] The title compound was obtained using butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 37

[0280] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide

[0281] The title compound was obtained using butylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 533 (M+H)+.

Example 38

[0282] rac-1-Butyl-5-[2-(2-chloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0283] The title compound was obtained using sec-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 430 (M+H)+.

Example 39

[0284] rac-1-Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide

[0285] The title compound was obtained using sec-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 40

[0286] rac-1-Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0287] The title compound was obtained using sec-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 41

[0288] rac-1-Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0289] The title compound was obtained using sec-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 425 (M+H)+.

Example 42

[0290] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0291] The tide compound was obtained using sec-butylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 430 (M+H)+.

Example 43

[0292] rac-1-Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0293] The title compound was obtained using sec-butylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 44

[0294] rac-1-Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0295] The title compound was obtained using sec-butylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 45

[0296] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0297] The title compound was obtained using sec-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as. R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 46

[0298] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0299] The title compound was obtained using sec-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 47

[0300] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0301] The title compound was obtained using sec-butylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 48

[0302] rac-1-Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0303] The title compound was obtained using sec-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 49

[0304] rac-1-Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0305] The title compound was obtained using sec-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 438 (M+H)+.

Example 50

[0306] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0307] The title compound was obtained using sec-butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 458 (M+H)+.

Example 51

[0308] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0309] The title compound was obtained using sec-butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)n—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 52

[0310] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0311] The title compound was obtained using sec-butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 484 (M+H)+.

Example 53

[0312] rac-2-Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0313] The title compound was obtained using sec-butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 54

[0314] rac 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0315] The title compound was obtained using sec-butylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 428 (M+H)+.

Example 55

[0316] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0317] The title compound was obtained using sec-butylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 56

[0318] rac-1-Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0319] The title compound was obtained using sec-butylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 450 (M+H)+.

Example 57

[0320] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0321] The title compound was obtained using sec-butylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 449 (M+H)+.

Example 58

[0322] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0323] The title compound was obtained using sec-butylamine as R1R2NH, 4-methoxybenzyl-amine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 494 (M+H)+.

Example 59

[0324] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0325] The title compound was obtained using sec-butylamine as R1R2NH, 4-methoxybenzyl-amine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 490 (M+H)+.

Example 60

[0326] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0327] The title compound was obtained using sec-butylamine as R1R2NH, 4-methoxybenzyl-amine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 520 (M+H)+.

Example 61

[0328] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0329] The title compound was obtained using sec-butylamine as R1R2NH, 4-methoxybenzyl-amine as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 489 (M+H)+.

Example 62

[0330] rac-1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0331] The title compound was obtained using sec-butylamine as R1R2NH, 4-methoxybenzyl-amine as R3— (CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 462 (M+H)+.

Example 63

[0332] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0333] The title compound was obtained using sec-butylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 442 (M+H)+.

Example 64

[0334] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide

[0335] The title compound was obtained using sec-butylamine as R1R2NH, methoxyethylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 472 (M+H)+.

Example 65

[0336] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0337] The title compound was obtained using sec-butylamine as R1R2NH, 3-(aminomethyl)-thiophene as R3— (CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 66

[0338] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0339] The title compound was obtained using sec-butylamine as R1R2NH, 3-(aminomethyl)-thiophene as R3— (CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 67

[0340] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0341] The title compound was obtained using sec-butylamine as R1R2NH, 3-(aminomethyl)-thiophene as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 68

[0342] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0343] The title compound was obtained using sec-butylamine as R1R2NH, 3-(aminomethyl)-thiophene as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 69

[0344] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide

[0345] The title compound was obtained using sec-butylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 538 (M+H)+.

Example 70

[0346] Butyl-5-[2-(2-chloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0347] The title compound was obtained using iso-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 430 (M+H)+.

Example 71

[0348] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0349] The title compound was obtained using iso-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 72

[0350] Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid isobutyl-amide

[0351] The title compound was obtained using iso-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 73

[0352] Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid isobutyl-amide

[0353] The title compound was obtained using iso-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 425 (M+H)+.

Example 74

[0354] Butyl-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid Isobutyl-amide

[0355] The title compound was obtained using iso-butylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 411 (M+H)+.

Example 75

[0356] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0357] The title compound was obtained using isobutylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 76

[0358] Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0359] The title compound was obtained using iso-butylamine as R1R2NH, isobutylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 77

[0360] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0361] The title compound was obtained using iso-butylamine as R1R2NH, isobutylamine as R3—(CH2)n—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 425 (M+H)+.

Example 78

[0362] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0363] The title compound was obtained using iso-butylamine as R1R2NH, 2-(4-methoxyphenyl)ethylamine as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 503 (M+H)+.

Example 79

[0364] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0365] The title compound was obtained using iso-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 80

[0366] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0367] The title compound was obtained using iso-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 81

[0368] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0369] The title compound was obtained using iso-butylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)n—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 82

[0370] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0371] The title compound was obtained using iso-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 83

[0372] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0373] The title compound was obtained using iso-butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 458 (M+H)+.

Example 84

[0374] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0375] The title compound was obtained using iso-butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 85

[0376] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0377] The title compound was obtained using iso-butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 484 (M+H)+.

Example 86

[0378] 4-[4-Isobutylcarbamoyl-5-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0379] The title compound was obtained using iso-butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 420 (M+H)+.

Example 87

[0380] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0381] The title compound was obtained using iso-butylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 439 (M+H)+.

Example 88

[0382] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0383] The title compound was obtained using iso-butylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 89

[0384] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0385] The title compound was obtained using iso-butylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 428 (M+H)+.

Example 90

[0386] 1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0387] The title compound was obtained using iso-butylamine as R1R2NH, methoxyethylamine as R3— (CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 400 (M+H)+.

Example 91

[0388] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0389] The title compound was obtained using iso-butylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 92

[0390] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0391] The title compound was obtained using iso-butylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 450 (M+H)+.

Example 93

[0392] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

100

[0393] The title compound was obtained using iso-butylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 449 (M+H)+.

Example 94

[0394] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

101

[0395] The title compound was obtained using iso-butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 490 (M+H)+.

Example 95

[0396] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

102

[0397] The title compound was obtained using iso-butylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)n—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 520 (M+H)+.

Example 96

[0398] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

103

[0399] The title compound was obtained using iso-butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 489 (M+H)+.

Example 97

[0400] 4-[4-Isobutylcarbamoyl-1-(4-methoxy-benzyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

104

[0401] The title compound was obtained using iso-butylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 98

[0402] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

105

[0403] The tide compound was obtained using iso-butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 475 (M+H)+.

Example 99

[0404] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

106

[0405] The tide compound was obtained using iso-butylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 462 (M+H)+.

Example 100

[0406] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

107

[0407] The title compound was obtained using iso-butylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 442 (M+H)+.

Example 101

[0408] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

108

[0409] The title compound was obtained using iso-butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 102

[0410] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

109

[0411] The title compound was obtained using iso-butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 103

[0412] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

110

[0413] The title compound was obtained using iso-butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 104

[0414] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

111

[0415] The title compound was obtained using iso-butylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 105

[0416] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-Carboxylic Acid allylamide

112

[0417] The title compound was obtained using allylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 410 (M+H)+.

Example 106

[0418] Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

113

[0419] The title compound was obtained using allylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 440 (M+H)+.

Example 107

[0420] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

114

[0421] The title compound was obtained using allylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 410 (M+H)+.

Example 108

[0422] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid allylamide

115

[0423] The title compound was obtained using allylamine as R1R2NH, 2-(4-methoxyphenyl)-ethylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 518 (M+H)+.

Example 109

[0424] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

116

[0425] The title compound was obtained using allylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 110

[0426] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Allylamide

117

[0427] The title compound was obtained using allylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 450 (M+H)+.

Example 111

[0428] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

118

[0429] The title compound was obtained using allylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 480 (M+H)+.

Example 112

[0430] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

119

[0431] The title compound was obtained using allylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 449 (M+H)+.

Example 113

[0432] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Allylamide

120

[0433] The title compound was obtained using allylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 422 (M+H)+.

Example 114

[0434] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Allylamide

121

[0435] The title compound was obtained using allylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 438 (M+H)+.

Example 115

[0436] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

122

[0437] The title compound was obtained using allylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 416 (M+H)+.

Example 116

[0438] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

123

[0439] The title compound was obtained using allylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 434 (M+H)+.

Example 117

[0440] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

124

[0441] The title compound was obtained using allylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 433 (M+H)+.

Example 118

[0442] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

125

[0443] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 478 (M+H)+.

Example 119

[0444] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

126

[0445] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)n—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 474 (M+H)+.

Example 120

[0446] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

127

[0447] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 504 (M+H)+.

Example 121

[0448] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

128

[0449] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine Carbothiamide as R4C(S)NH2, MS(ES+) 473 (M+H)+.

Example 122

[0450] 4-[4-Allylcarbamoyl-1-(4-methoxy-benzyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

129

[0451] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 440 (M+H)+.

Example 123

[0452] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Allylamide

130

[0453] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 459 (M+H)+.

Example 124

[0454] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Allylamide

131

[0455] The title compound was obtained using allylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 446 (M+H)+.

Example 125

[0456] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Allylamide

132

[0457] The title compound was obtained using allylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 450 (M+H)+.

Example 126

[0458] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Allylamide

133

[0459] The title compound was obtained using allylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 490 (M+H)+.

Example 127

[0460] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

134

[0461] The title compound was obtained using aminomethylcyclohexane as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 128

[0462] Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

135

[0463] The title compound was obtained using aminomethylcyclohexane as R1R2NH, butylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 129

[0464] Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylmethyl-amide

136

[0465] The title compound was obtained using aminomethylcyclohexane as R1R2NH, butylamine as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 130

[0466] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

137

[0467] The title compound was obtained using aminomethylcyclohexane as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 131

[0468] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

138

[0469] The title compound was obtained using aminomethylcyclohexane as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 132

[0470] Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

139

[0471] The title compound was obtained using aminomethylcyclohexane as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 133

[0472] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

140

[0473] The title compound was obtained using aminomethylcyclohexane as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 438 (M+H)+.

Example 134

[0474] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

141

[0475] The title compound was obtained using aminomethylcyclohexane as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 506 (M+H)+.

Example 135

[0476] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

142

[0477] The title compound was obtained using aminomethylcyclohexane as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 505 (M+H)+.

Example 136

[0478] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

143

[0479] The title compound was obtained using aminomethylcyclohexane as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 478 (M+H)+.

Example 137

[0480] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

144

[0481] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 138

[0482] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

145

[0483] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 494 (M+H)+.

Example 139

[0484] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid cyclohexylmethyl-amide

146

[0485] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 524 (M+H)+.

Example 140

[0486] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

147

[0487] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 493 (M+H)+.

Example 141

[0488] 4-[4-(Cyclohexylmethyl-carbamoyl)-5-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

148

[0489] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and ethylthiooxamate, MS(ES+) 460 (M+H)+.

Example 142

[0490] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

149

[0491] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfirylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2. xx479

Example 143

[0492] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

150

[0493] The title compound was obtained using aminomethylcyclohexane as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 144

[0494] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

151

[0495] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 472 (M+H)+.

Example 145

[0496] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

152

[0497] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 468 (M+H)+.

Example 146

[0498] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

153

[0499] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 147

[0500] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

154

[0501] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 467 (M+H)+.

Example 148

[0502] 4-[4-(Cyclohexylmethyl-carbamoyl)-1-(2-methoxy-ethyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

155

[0503] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2., MS(ES+) 434 (M+H)+.

Example 149

[0504] 1-(2-Methoxy-ethyl)-2methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3carboxylic Acid Cyclohexylmethyl-amide

156

[0505] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 453 (M+H)+.

Example 150

[0506] 1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

157

[0507] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 440 (M+H)+.

Example 151

[0508] 1-(2-Cyclohex-1-enyl-ethyl)-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylmethyl-amide

158

[0509] The title compound was obtained using aminomethylcyclohexane as R1R2NH, 2-(1-cyclohexenyl)ethylamine as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 517 (M+H)+.

Example 152

[0510] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

159

[0511] The tide compound was obtained using aminomethylcyclohexane as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 490 (M+H)+.

Example 153

[0512] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

160

[0513] The title compound was obtained using aminomethylcyclohexane as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 534 (M+H)+.

Example 154

[0514] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

161

[0515] The title compound was obtained using aminomethylcyclohexane as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 530 (M+H)+.

Example 155

[0516] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

162

[0517] The title compound was obtained using aminomethylcyclohexane as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 529 (M+H)+.

Example 156

[0518] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

163

[0519] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 486 (M+H)+.

Example 157

[0520] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

164

[0521] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 158

[0522] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

165

[0523] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 512 (M+H)+.

Example 159

[0524] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

166

[0525] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 481 (M+H)+.

Example 160

[0526] 4-[4-(Cyclohexylmethyl-carbamoyl)-1-(3-methoxy-propyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

167

[0527] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2., MS(ES+) 448 (M+H)+.

Example 161

[0528] 1-(3-Methoxy-propyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

168

[0529] The title compound was obtained using aminomethylcyclohexane as R1R2NH, methoxyethylamine as R3— (CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 162

[0530] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

169

[0531] The title compound was obtained using aminomethylcyclohexane as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 506 (M+H)+.

Example 163

[0532] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

170

[0533] The title compound was obtained using aminomethylcyclohexane as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 505 (M+H)+.

Example 164

[0534] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

171

[0535] The title compound was obtained using aminomethylcyclohexane as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 578 (M+H)+.

Example 165

[0536] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

172

[0537] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 166

[0538] 4-{1-Isobutyl-5-methyl-4-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrrol-2-yl}-thiazole-2-carboxylic acid ethyl ester

173

[0539] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 420. (M+H)+.

Example 167

[0540] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

174

[0541] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 168

[0542] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

175

[0543] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 169

[0544] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

176

[0545] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)n—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 494 (M+H)+.

Example 170

[0546] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

177

[0547] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 524 (M+H)+.

Example 171

[0548] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

178

[0549] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 493 (M+H)+.

Example 172

[0550] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

179

[0551] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 173

[0552] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

180

[0553] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 486 (M+H)+.

Example 174

[0554] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

181

[0555] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 175

[0556] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

182

[0557] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 455 (M+H)+.

Example 176

[0558] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

183

[0559] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 177

[0560] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

184

[0561] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 478 (M+H)+.

Example 178

[0562] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

185

[0563] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 477 (M+H)+.

Example 179

[0564] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

186

[0565] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and thioacetamide as R4C(S)NH2, MS(ES+) 426 (M+H)+.

Example 180

[0566] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

187

[0567] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 522 (M+H)+.

Example 181

[0568] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

188

[0569] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 518 (M+H)+.

Example 182

[0570] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

189

[0571] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 548 (M+H)+.

Example 183

[0572] 4-{1-(4-Methoxy-benzyl)-5-methyl-4-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrrol-2-yl}-thiazole-2-carboxylic Acid Ethyl Ester

190

[0573] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2., MS(ES+) 484 (M+H)+.

Example 184

[0574] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

191

[0575] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 503 (M+H)+.

Example 185

[0576] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

192

[0577] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 490 (M+H)+.

Example 186

[0578] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

193

[0579] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 469 (M+H)+.

Example 187

[0580] 1-(3-Methoxy-propyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

194

[0581] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 455 (M+H)+.

Example 188

[0582] 1-(3-Methoxy-propyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

195

[0583] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 442 (M+H)+.

Example 189

[0584] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

196

[0585] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 190

[0586] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

197

[0587] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 494 (M+H)+.

Example 191

[0588] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

198

[0589] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 493 (M+H)+.

Example 192

[0590] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

199

[0591] The title compound was obtained using tetrahydrofurfurylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 561 (M+H)+.

Example 193

[0592] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

200

[0593] The title compound was obtained using methoxyethylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 428 (M+H)+.

Example 194

[0594] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

201

[0595] The title compound was obtained using methoxyethylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 472 (M+H)+.

Example 195

[0596] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

202

[0597] The title compound was obtained using methoxyethylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 468 (M+H)+.

Example 196

[0598] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

203

[0599] The tide compound was obtained using methoxyethylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 197

[0600] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

204

[0601] The tide compound was obtained using methoxyethylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 440 (M+H)+.

Example 198

[0602] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

205

[0603] The title compound was obtained using methoxyethylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 199

[0604] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

206

[0605] The title compound was obtained using methoxyethylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 430 (M+H)+.

Example 200

[0606] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid (2-methoxy-ethyl)-amide

207

[0607] The title compound was obtained using methoxyethylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 201

[0608] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

208

[0609] The title compound was obtained using methoxyethylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 452 (M+H)+.

Example 202

[0610] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

209

[0611] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 203

[0612] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

210

[0613] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 492 (M+H)+.

Example 204

[0614] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-methoxy-ethyl)-amide

211

[0615] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 522 (M+H)+.

Example 205

[0616] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

212

[0617] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 491 (M+H)+.

Example 206

[0618] 4-[1-(4-Methoxy-benzyl)-4-(2-methoxy-ethylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic acid ethyl ester

213

[0619] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2., MS(ES+) 458 (M+H)+.

Example 207

[0620] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

214

[0621] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 477 (M+H)+.

Example 208

[0622] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

215

[0623] The title compound was obtained using methoxyethylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 464 (M+H)+.

Example 209

[0624] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-methoxy-ethyl)-amide

216

[0625] The title compound was obtained using methoxyethylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 535 (M+H)+.

Example 210

[0626] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

217

[0627] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 478 (M+H)+.

Example 211

[0628] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

218

[0629] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 518 (M+H)+.

Example 212

[0630] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

219

[0631] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2 NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 517 (M+H)+.

Example 213

[0632] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid (2-cyclohex-1-enyl-ethyl)-amide

220

[0633] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, tetrahydrofurfirylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 506 (M+H)+.

Example 214

[0634] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

221

[0635] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 505 (M+H)+.

Example 215

[0636] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

222

[0637] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 491 (M+H)+.

Example 216

[0638] 1-(2-Methoxy-ethyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

223

[0639] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 465 (M+H)+.

Example 217

[0640] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

224

[0641] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 501 (M+H)+.

Example 218

[0642] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

225

[0643] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 541 (M+H)+.

Example 219

[0644] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

226

[0645] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 527 (M+H)+.

Example 220

[0646] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

227

[0647] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 517 (M+H)+.

Example 221

[0648] rac-1-Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

228

[0649] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 222

[0650] rac-1-Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

229

[0651] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 512 (M+H)+.

Example 223

[0652] rac-1-Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

230

[0653] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 481 (M+H)+.

Example 224

[0654] rac-4-[1-Butyl-4-(2-ethyl-hexylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

231

[0655] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, butylamine as R3—(CH2)n—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 448 (M+H)+.

Example 225

[0656] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

232

[0657] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 486 (M+H)+.

Example 226

[0658] rac-1-Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

233

[0659] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 227

[0660] rac-1-Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

234

[0661] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, isobutylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 512 (M+H)+.

Example 228

[0662] rac-4-[4-(2-Ethyl-hexylcarbamoyl)-1-isobutyl-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

235

[0663] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 44 (M+H)+0.8

Example 229

[0664] rac-1-Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

236

[0665] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 230

[0666] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

237

[0667] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 2-(1-cyclohexenyl)ethylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 590 (M+H)+.

Example 231

[0668] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

238

[0669] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 2-(1-cyclohexenyl)ethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 559 (M+H)+.

Example 232

[0670] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

239

[0671] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 526 (M+H)+.

Example 233

[0672] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

240

[0673] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 522 (M+H)+.

Example 234

[0674] rac-1-Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

241

[0675] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 521 (M+H)+.

Example 235

[0676] rac-4-[1-Cyclohexylmethyl-4-(2-ethyl-hexylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

242

[0677] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2., MS(ES+) 488 (M+H)+.

Example 236

[0678] rac-1-Cyclohexylmethyl-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

243

[0679] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 507 (M+H)+.

Example 237

[0680] rac-1-Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

244

[0681] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 494 (M+H)+.

Example 238

[0682] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

245

[0683] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 514 (M+H)+.

Example 239

[0684] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

246

[0685] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 510 (M+H)+.

Example 240

[0686] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

247

[0687] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 540 (M+H)+.

Example 241

[0688] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

248

[0689] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 509 (M+H)+.

Example 242

[0690] rac-4-[4-(2-Ethyl-hexylcarbamoyl)-5-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

249

[0691] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 476 (M+H)+.

Example 243

[0692] rac-2-Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

250

[0693] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 495 (M+H)+.

Example 244

[0694] rac-2-Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

251

[0695] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 245

[0696] rac-1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

252

[0697] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 484 (M+H)+.

Example 246

[0698] rac-1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

253

[0699] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 514 (M+H)+.

Example 247

[0700] rac-1-(2-Methoxy-ethyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

254

[0701] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 469 (M+H)+.

Example 248

[0702] rac-1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

255

[0703] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 456 (M+H)+.

Example 249

[0704] rac-1-(2-Cyclohex-1-enyl-ethyl)-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

256

[0705] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 2-(1-cyclohexenyl)ethylamine as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 533 (M+H)+.

Example 250

[0706] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

257

[0707] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 510 (M+H)+.

Example 251

[0708] rac-1-Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

258

[0709] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)n—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 506 (M+H)+.

Example 252

[0710] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

259

[0711] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 505 (M+H)+.

Example 253

[0712] rac-1-(4-Methoxy-benzyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

260

[0713] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and thioacetamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 254

[0714] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

261

[0715] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 550 (M+H)+.

Example 255

[0716] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

262

[0717] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 546 (M+H)+.

Example 256

[0718] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

263

[0719] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 576 (M+H)+.

Example 257

[0720] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

264

[0721] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 545 (M+H)+.

Example 258

[0722] rac-1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

265

[0723] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 531 (M+H)+.

Example 259

[0724] rac-1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

266

[0725] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 518 (M+H)+.

Example 260

[0726] rac-1-(3-Methoxy-propyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

267

[0727] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and thioacetamide as R4C(S)NH2, MS(ES+) 406 (M+H)+.

Example 261

[0728] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

268

[0729] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 262

[0730] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

269

[0731] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 528 (M+H)+.

Example 263

[0732] rac-4-[4-(2-Ethyl-hexylcarbamoyl)-1-(3-methoxy-propyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

270

[0733] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethyl-amine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS (ES+) 564 (M+H)+.

Example 264

[0734] rac-1-(3-Methoxy-propyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

271

[0735] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, methoxyethylamine as R3— (CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 265

[0736] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

272

[0737] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 526 (M+H)+.

Example 266

[0738] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

273

[0739] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 522 (M+H)+.

Example 267

[0740] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

274

[0741] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 552 (M+H)+.

Example 268

[0742] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

275

[0743] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, 3-(aminomethyl)thiophene as R3— (CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 521 (M+H)+.

Example 269

[0744] rac-1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

276

[0745] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and thioacetamide as R4C(S)NH2, MS(ES+) 498 (M+H)+.

Example 270

[0746] rac-1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

277

[0747] The title compound was obtained using 2-ethyl-hexylamine as R1R2NH, homoveratrylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 620 (M+H)+.

Example 271

[0748] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (3-methoxy-propyl)-amide

278

[0749] The title compound was obtained using methoxypropylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 442 (M+H)+.

Example 272

[0750] Butyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

279

[0751] The title compound was obtained using methoxypropylamine as R1R2NH, butylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 414 (M+H)+.

Example 273

[0752] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

280

[0753] The title compound was obtained using methoxypropylamine as R1R2NH, isobutylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 414 (M+H)+.

Example 274

[0754] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

281

[0755] The title compound was obtained using methoxypropylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 486 (M+H)+.

Example 275

[0756] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

282

[0757] The title compound was obtained using methoxypropylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 276

[0758] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

283

[0759] The title compound was obtained using methoxypropylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 512 (M+H)+.

Example 277

[0760] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

284

[0761] The title compound was obtained using methoxypropylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 481 (M+H)+.

Example 278

[0762] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

285

[0763] The title compound was obtained using methoxypropylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 454 (M+H)+.

Example 279

[0764] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

286

[0765] The title compound was obtained using methoxypropylamine as R1R2NH, tetrahydrofurfurylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 280

[0766] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

287

[0767] The title compound was obtained using methoxypropylamine as R1R2NH, tetrahydrofurfurylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 500 (M+H)+.

Example 281

[0768] 1-(2-Cyclohex-1-enyl-ethyl)-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

288

[0769] The title compound was obtained using methoxypropylamine as R1R2NH, 2-(1-cyclohexenyl)ethylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 493 (M+H)+.

Example 282

[0770] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

289

[0771] The title compound was obtained using methoxypropylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 470 (M+H)+.

Example 283

[0772] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

290

[0773] The title compound was obtained using methoxypropylamine as R1R2NH, 3-furylmethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 466 (M+H)+.

Example 284

[0774] Furan-2-ylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

291

[0775] The title compound was obtained using methoxypropylamine as R1R2NH, 3-furylmethylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 496 (M+H)+.

Example 285

[0776] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

292

[0777] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and thioacetamide as R4C(S)NH2, MS(ES+) 414 (M+H)+.

Example 286

[0778] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

293

[0779] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 510 (M+H)+.

Example 287

[0780] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

294

[0781] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2. 506

Example 288

[0782] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

295

[0783] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 536 (M+H)+.

Example 289

[0784] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

296

[0785] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 289 (M+H)+.

Example 290

[0786] 4-[1-(4-Methoxy-benzyl)-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

297

[0787] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2., MS(ES+) 472 (M+H)+.

Example 291

[0788] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

298

[0789] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3— (CH2)m—NH2 and 6-methyl-pyridine-3-carbothioamide as R4C(S)NH2, MS(ES+) 491 (M+H)+.

Example 292

[0790] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (3-methoxy-propyl)-amide

299

[0791] The title compound was obtained using methoxypropylamine as R1R2NH, 4-methoxybenzylamine as R3—(CH2)m—NH2 and pyrazine-2-carbothioamide as R4C(S)NH2, MS(ES+) 478 (M+H)+.

Example 293

[0792] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

300

[0793] The title compound was obtained using methoxypropylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-chloro-phenyl thioamide as R4C(S)NH2, MS(ES+) 486 (M+H)+.

Example 294

[0794] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

301

[0795] The title compound was obtained using methoxypropylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ES+) 482 (M+H)+.

Example 295

[0796] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

302

[0797] The title compound was obtained using methoxypropylamine as R1R2NH, 3-(aminomethyl)thiophene as R3—(CH2)m—NH2 and 2-ethyl-4-pyridine carbothiamide as R4C(S)NH2, MS(ES+) 481 (M+H)+.

Example 296

[0798] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

303

[0799] The title compound was obtained using methoxypropylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and 2-(4-methoxyphenoxy)ethanethioamide as R4C(S)NH2, MS(ES+) 580 (M+H)+.

Example 297

[0800] 4-[1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

304

[0801] The title compound was obtained using methoxypropylamine as R1R2NH, homoveratrylamine as R3—(CH2)m—NH2 and ethylthiooxamate as R4C(S)NH2, MS(ES+) 516 (M+H)+.

Example 298

[0802] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid morpholin-4-ylamide

305

[0803] The title compound was obtained using 1-amino-morpholine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 495.3 (M+H)+.

Example 299

[0804] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid piperidin-1-ylamide

306

[0805] The title compound was obtained using 1-amino-piperidine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 493.4 (M+H)+.

Example 300

[0806] 1-(4-Chloro-phenyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid butylamide

307

[0807] The title compound was obtained using butylamine as R1R2NH, 4-chloroaniline as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 480.3 (M+H)+.

Example 301

[0808] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3,4-dimethoxy-phenyl)-amide

308

[0809] The title compound was obtained using 3,4-dimethoxy aniline as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 546.3 (M+H)+.

Example 302

[0810] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-nitro-phenyl)-amide

[0811] The title compound was obtained using 2-nitroaniline as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 531.3 (M+H)+.

309

Example 303

[0812] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-trifluoromethyl-phenyl)-amide

310

[0813] The title compound was obtained using 4-trifluoromethylaniline as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 554.3 (M+H)+.

Example 304

[0814] N′-{1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carbonyl}-hydrazinecarboxylic Acid Ethyl Ester.

311

[0815] The title compound was obtained using ethyl carbazate as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 497.4 (M+H)+.

Example 305

[0816] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (pyridin-2-ylmethyl)-amide

312

[0817] The title compound was obtained using 2-(aminomethyl)pyridine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 501.3 (M+H)+.

Example 306

[0818] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-chloro-phenyl)-amide

313

[0819] The title compound was obtained using 4-chloro-aniline as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 520.3 (M+H)+.

Example 307

[0820] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3,4-dichloro-phenyl)-amide

314

[0821] The title compound was obtained using 3,4-dichloroaniline as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 554.3 (M+H)+.

Example 308

[0822] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid sec-butylamide

315

[0823] The title compound was obtained using sec-butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 466.4 (M+H)+.

Example 309

[0824] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-morpholin-4-yl-methanone.

316

[0825] The title compound was obtained using morpholine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 480.3 (M+H)+.

Example 310

[0826] Methyl-isoxazole-3-carboxylic acid N′-{1-cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carbonyl}-hydrazide.

317

[0827] The title compound was obtained using 5-methylisoxazole-3-carbohydrazide as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 534.3 (M+H)+.

Example 311

[0828] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone.

318

[0829] The title compound was obtained using piperidine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 478.3 (M+H)+.

Example 312

[0830] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-phenethyl-1H-pyrrole-3-carboxylic Acid Butylamide

319

[0831] The title compound was obtained using butylamine as R1R2NH, phenethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 474.3 (M+H)+.

Example 313

[0832] 1-(2-Cyclohexyl-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

320

[0833] The title compound was obtained using butylamine as R1R2NH, 2-cyclohexyl-ethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 480.4 (M+H)+.

Example 314

[0834] 1-(3,5-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

321

[0835] The title compound was obtained using butylamine as R1R2NH, 3,5-dimethylbenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 488.3 (M+H)+.

Example 315

[0836] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Phenylamide

322

[0837] The title compound was obtained using aniline as R1R2 NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 486.4 (M+H)+.

Example 316

[0838] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(4-phenyl-butyl)-1H-pyrrole-3-carboxylic Acid Butylamide

323

[0839] The title compound was obtained using butylamine as R1R2NH, 4-phenylbutylamine as R3—(CH2)n—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 502.3 (M+H)+.

Example 317

[0840] 1-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

324

[0841] The title compound was obtained using butylamine as R1R2NH, 2-(aminomethyl)-1-ethylpyrrolidine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 481.3 (M+H)+.

Example 318

[0842] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Amide

325

[0843] The title compound was obtained using aminomethylcyclohexane as R3—(CH2)n-NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 410.3 (M+H)+.

Example 319

[0844] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-morpholin-4-yl-ethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

326

[0845] The title compound was obtained using butylamine as R1R2NH, 4-(2-aminoethyl)morpholine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 483.3 (M+H)+.

Example 320

[0846] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-methyl-thiazol-2-yl)-amide

327

[0847] The title compound was obtained using 2-amino-4-methylthiazole as R1R2 NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 507.3 (M+H)+.

Example 321

[0848] 1-(3-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

328

[0849] The title compound was obtained using butylamine as R1R2NH, 3-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 490.3 (M+H)+.

Example 322

[0850] 1-(3,5-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

329

[0851] The title compound was obtained using butylamine as R1R2NH, 3,5-dichloroaniline as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 528.2 (M+H)+.

Example 323

[0852] Indan-2-yl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

330

[0853] The title compound was obtained using butylamine as R1R2NH, 2-aminoindane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 486.4 (M+H)+.

Example 324

[0854] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid pyrimidin-2-ylamide

331

[0855] The title compound was obtained using 2-aminopyrimidine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 488.3 (M+H)+.

Example 325

[0856] 1-(3,4-Dihydroxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

332

[0857] The title compound was obtained using butylamine as R1R2NH, 3,4-dihydroxybenzylamine as R3—(CH2)n—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 492.3 (M+H)+.

Example 326

[0858] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-piperidin-1-yl-propyl)-1H-pyrrole-3-carboxylic acid butylamide

333

[0859] The title compound was obtained using butylamine as R1R2NH, 3-piperidino-propylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 495.4 (M+H)+.

Example 327

[0860] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (5-hydroxy-2,2,6-trimethyl-cyclohexylmethyl)-amide

334

[0861] The title compound was obtained using aminomethylcyclohexane as R3—(CH2)m-NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 564.4 (M+H)+.

Example 328

[0862] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

335

[0863] The title compound was obtained using butylamine as R1R2NH, 3-(trifluoromethoxy)benzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 544.4 (M+H)+.

Example 329

[0864] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(4-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

336

[0865] The title compound was obtained using butylamine as R1R2NH, 4-(trifluoromethoxy)benzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 544.3 (M+H)+.

Example 330

[0866] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-methyl-thiophen-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

337

[0867] The title compound was obtained using butylamine as R1R2NH, (3-methyl-2-thienyl)methylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 480.3 (M+H)+.

Example 331

[0868] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(4-nitro-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

338

[0869] The title compound was obtained using butylamine as R1R2NH, 4-nitrobenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 505.4 (M+H)+.

Example 332

[0870] Benzhydryl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Butylamide

339

[0871] The title compound was obtained using butylamine as R1R2NH, benzhydrylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 536.4 (M+H)+.

Example 333

[0872] Benzyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

340

[0873] The title compound was obtained using butylamine as R1R2NH, benzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 560.3 (M+H)+.

Example 334

[0874] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-pyridin-2-yl-ethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

341

[0875] The title compound was obtained using butylamine as R1R2NH, 2-(2-aminoethyl)pyridine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 475.3 (M+H)+.

Example 335

[0876] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-pyrrolidin-1-yl-methanone

342

[0877] The title compound was obtained using pyrrolidine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 464.3 (M+H)+.

Example 336

[0878] Cyclohexylmethyl-5-[2-(3,4-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

343

[0879] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 3,4-dimethoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 496.4 (M+H)+.

Example 337

[0880] Cyclohexylmethyl-5-[2-(2-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

344

[0881] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 3,4-dimethoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 466.3 (M+H)+.

Example 338

[0882] Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

345

[0883] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-trifluoromethylphenyl thioamide as R4C(S)NH2, MS(ISP) 504.2 (M+H)+.

Example 339

[0884] Cyclohexylmethyl-5-[2-(3-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

346

[0885] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 3-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 466.3 (M+H)+.

Example 340

[0886] 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

347

[0887] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 1,3-benzodioxole-5-carbothiamide as R4C(S)NH2, MS(ISP) 480.3 (M+H)+.

Example 341

[0888] Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

348

[0889] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-fluorophenyl thioamide as R4C(S)NH2, MS(ISP) 454.3 (M+H)+.

Example 342

[0890] Cyclohexylmethyl-5-[2-(2-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

349

[0891] The tide compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2-fluorophenyl thioamide as R4C(S)NH2, MS(ISP) 454.3 (M+H)+.

Example 343

[0892] Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

350

[0893] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-(trifluoromethoxy)phenyl thioamide as R4C(S)NH2, MS(ISP) 520.3 (M+H)+.

Example 344

[0894] Cyclohexylmethyl-5-[2-(3,5-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

351

[0895] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 3,5-dimethoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 496.4 (M+H)+.

Example 345

[0896] Cyclohexylmethyl-2-methyl-5-(2-m-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

352

[0897] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 3-methylphenyl thioamide as R4C(S)NH2, MS(ISP) 450.3 (M+H)+.

Example 346

[0898] Cyclohexylmethyl-2-methyl-5-(2′-methyl-[2,4′]bithiazolyl-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

353

[0899] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3— (CH2)m—NH2 and 2-methyl-1,3-thiazole-4-carbothioamide as R4C(S)NH2, MS(ISP) 457.3 (M+H)+.

Example 347

[0900] Cyclohexylmethyl-5-[2-(4-ethyl-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

354

[0901] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)n—NH2 and 4-ethylphenyl thioamide as R4C(S)NH2, MS(ISP) 464.3 (M+H)+.

Example 348

[0902] 5-[2-(4-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

355

[0903] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-chlorophenyl thioamide as R4C(S)NH2, MS(ISP) 470.3 (M+H)+.

Example 349

[0904] 5-[2-(4-tert-Butyl-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

356

[0905] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-tertbutylphenyl thioamide as R4C(S)NH2, MS(ISP) 492.4 (M+H)+.

Example 350

[0906] Cyclohexylmethyl-5-[2-(2,3-dihydro-benzofuran-5-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

357

[0907] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2,3-dihydrobenzo[b]furan-5-carbothioamide as R4C(S)NH2, MS(ISP) 478.3 (M+H)+.

Example 351

[0908] Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

358

[0909] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methylphenyl thioamide as R4C(S)NH2, MS(ISP) 450.3 (M+H)+.

Example 352

[0910] Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

359

[0911] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 6-methoxy-nicotamide as R4C(S)NH2, MS(ISP) 467.3 (M+H)+.

Example 353

[0912] Cyclohexylmethyl-5-[2-(2,4-dichloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

360

[0913] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 2,4-dichlorophenyl thioamide as R4C(S)NH2, MS(ISP) 504.2 (M+H)+.

Example 354

[0914] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Pentylamide

361

[0915] The title compound was obtained using pentylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 481.3 (M+H)+.

Example 355

[0916] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Propylamide

362

[0917] The title compound was obtained using propylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 452.3 (M+H)+.

Example 356

[0918] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylamide

363

[0919] The title compound was obtained using cyclohexylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 492.3 (M+H)+.

Example 357

[0920] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclopentylamide

364

[0921] The title compound was obtained using cyclopentylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 478.3 (M+H)+.

Example 358

[0922] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclopropylamide

365

[0923] The title compound was obtained using cyclopropylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 450.3 (M+H)+.

Example 359

[0924] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclobutylamide

366

[0925] The title compound was obtained using cyclobutylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 464.3 (M+H)+.

Example 360

[0926] (trans) rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-hydroxy-cyclopentyl)-amide

367

[0927] The title compound was obtained using trans-2-aminocyclopentanol as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 494.3 (M+H)+.

Example 361

[0928] 1-(4-Chloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

368

[0929] The title compound was obtained using butylamine as R1R2NH, 4-chloroaniline as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 494.2 (M+H)+.

Example 362

[0930] 1-(3,4-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

369

[0931] The title compound was obtained using butylamine as R1R2NH, 3,4-dichloroaniline as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as —R4C(S)NH2, MS(ISP) 527.2 (M+H)+.

Example 363

[0932] 1-(4-Chloro-3-trifluoromethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

370

[0933] The title compound was obtained using butylamine as R1R2NH, 3-trifluoromethyl,4-chloro aniline as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 562.2 (M+H)+.

Example 364

[0934] 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

371

[0935] The title compound was obtained using butylamine as R1R2NH, 3,4-dimethylbenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 488.3 (M+H)+.

Example 365

[0936] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-methyl-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

372

[0937] The title compound was obtained using butylamine as R1R2NH, 2-methylbenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 474.3 (M+H)+.

Example 366

[0938] 1-(3,4-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

373

[0939] The title compound was obtained using butylamine as R1R2NH, 3,4-dimethoxybenzyl-amine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 520.4 (M+H)+.

Example 367

[0940] 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

374

[0941] The title compound was obtained using butylamine as R1R2NH, 2,4-dimethoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 520.3 (M+H)+.

Example 368

[0942] 1-(3,5-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

375

[0943] The title compound was obtained using butylamine as R1R2NH, 3,5-methoxybenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 520.3 (M+H)+.

Example 369

[0944] Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

376

[0945] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-hydroxyphenyl thioamide as R4C(S)NH2, MS(ISP) 452.3 (M+H)+.

Example 370

[0946] 1-(4-Isopropyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

377

[0947] The title compound was obtained using butylamine as R1R2NH, 4-isopropylbenzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 502.3 (M+H)+.

Example 371

[0948] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

378

[0949] The title compound was obtained using butylamine as R1R2NH, 2-(aminomethyl)pyridine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2, MS(ISP) 461.3 (M+H)+.

Example 372

[0950] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-trifluoromethoxy-phenyl)-amide

379

[0951] The title compound was obtained using 4-(trifluoromethoxy)aniline as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2. MS(ISP) 569.6 (M+H)+.

Example 373

[0952] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3,4,5-trimethoxy-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

380

[0953] The title compound was obtained using butylamine as R1R2NH, 3,4,5-trimethoxy-benzylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2. MS(ISP) 549.2 (M+H)+.

Example 374

[0954] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-p-tolyl-ethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

381

[0955] The title compound was obtained using butylamine as R1R2NH, 2-(p-tolyl)ethylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2. MS(ISP) 487.6 (M+H)+.

Example 375

[0956] Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

382

[0957] The title compound was obtained using butylamine as R1R2NH, aminomethylcyclohexane as R3—(CH2)m—NH2 and cyclohexane carbothioamide as R4C(S)NH2. MS(ISP) 441.68 (M+H)+.

Example 376

[0958] Cyclohexyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Cyclopropylmethyl-amide

383

[0959] The title compound was obtained using cyclopropylmethylamine as R1R2NH, cyclohexylamine as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2. MS(ISP) 450.3 (M+H)+.

Example 377

[0960] rac 1-(5-Hydroxy-1,3,3-trimethyl-cyclohexylmethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

384

[0961] The title compound was obtained using butylamine as R1R2NH, 3-aminomethyl-3,5,5-trimethyl-cyclohexanol as R3—(CH2)m—NH2 and 4-methoxyphenyl thioamide as R4C(S)NH2. MS(ISP) 524.4 (M+H)+.

Galenical Examples

Example A

[0962] Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

2IngredientsPer tabletKernel:Compound of formula (I)10.0 mg 200.0 mg Microcrystalline cellulose23.5 mg 43.5 mg Lactose hydrous60.0 mg 70.0 mg Povidone K3012.5 mg 15.0 mg Sodium starch glycolate12.5 mg 17.0 mg Magnesium stearate1.5 mg4.5 mg(Kernel Weight)120.0 mg 350.0 mg Film Coat:Hydroxypropyl methyl cellulose3.5 mg7.0 mgPolyethylene glycol 60000.8 mg1.6 mgTalc1.3 mg2.6 mgIron oxyde (yellow)0.8 mg1.6 mgTitan dioxide0.8 mg1.6 mg

[0963] The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution/suspension of the above mentioned film coat.

Example B

[0964] Capsules containing the following ingredients can be manufactured in a conventional manner:

3IngredientsPer capsuleCompound of formula (I)25.0 mgLactose150.0 mg Maize starch20.0 mgTalc 5.0 mg

[0965] The components are sieved and mixed and filled into capsules of size 2.

Example C

[0966] Injection solutions can have the following composition:

4Compound of formula (I)3.0mgPolyethylene glycol 400150.0mgAcetic acidq.s.ad pH 5.0Water for injection solutionsad 1.0ml

[0967] The active ingredient is dissolved in a mixture of Polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by addition of acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.

Novel pyrrolyl-thiazole derivatives

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)